基因丰富的临床试验用于精确开发非癌症疗法:一个范围审查
Benoît Delabays1, Chiara De Paoli2, Andrea Miller-Nesbitt3
1Canada Excellence Research Chair in Genomic Medicine, Department of Human Genetics, Faculty of Medicine and Health Sciences, Victor Phillip Dahdaleh Institute of Genomic Medicine, McGill University, Montréal, Quebec, Canada;
基因丰富的临床试验是可行的和可扩展的,加速治疗的发展. 这份对110种药物的综述显示,60%的已完成研究达到其主要终点,支持精准医学.
科学领域:
- 药物基因组学 药物基因组学
- 临床试验设计 临床试验设计
- 药物开发 药物开发
背景情况:
- 基因驱动的临床试验丰富是一种提议的策略,以加快和降低与开发新疗法相关的成本.
- 缺乏对这种方法的使用和结果的全面审查.
结论:
- 基因丰富的临床试验被证明是可行的,并且可以在广泛的疾病领域进行扩展.
- 这些试验为推进或停止研究药物的开发提供了关键数据,与精准医学目标保持一致.
- 建立大型,设计精良的生物库对于促进未来的精密药物开发至关重要.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
What is Genetic Engineering?
